Kyverna Therapeutics, Inc. KYTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.19M-43.4% | $124.09M+28.4% | $34.16M-67.4% | $53.44M-59.4% | $56.87M-74.6% | ||
| $204.25M+9.9% | $155.16M-18.1% | $136.97M-36.9% | $158.24M— | $185.78M— | ||
| $241.73M-2.4% | $282.95M-2.6% | $174.93M-46.2% | $214.33M— | $247.65M— | ||
| $1.34M-44.9% | $1.55M-53.8% | $1.79M-43.1% | $2.16M— | $2.44M— | ||
| $257.02M-1.4% | $293.83M-3.6% | $187.16M-44.8% | $226.51M— | $260.66M— | ||
| $29.84M+7.0% | $26.71M-0.6% | $26.03M-2.2% | $32.95M+91.8% | $27.89M+118% | ||
| $221K-56.4% | $307K-60.6% | $190K-79.6% | $292K— | $507K— | ||
| $29.67M-10.9% | $36.49M+8.1% | $33.87M+9.3% | $39.79M— | $33.29M— | ||
| $61.44M+67.7% | $61.55M+61.7% | $35.21M-3.5% | $42.13M— | $36.65M— | ||
| —— | —— | —— | —— | —— | ||
| -$464.56M-50.8% | -$424.83M-61.2% | -$387.02M-71.2% | -$350.24M— | -$308.16M— | ||
| $195.58M-12.7% | $232.28M-12.9% | $151.95M-49.8% | $184.38M-44.7% | $224.01M-37.9% | ||
| $257.02M-1.4% | $293.83M-3.6% | $187.16M-44.8% | $226.51M— | $260.66M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kyverna Therapeutics, Inc.'s total assets?
- Kyverna Therapeutics, Inc. (KYTX) holds $257.0M in total assets, down 1.4% year over year.
- How much debt does Kyverna Therapeutics, Inc. have?
- Kyverna Therapeutics, Inc. carries $9.2M in total debt against $195.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kyverna Therapeutics, Inc. have?
- Kyverna Therapeutics, Inc. holds $32.2M in cash and equivalents.
- Can Kyverna Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.15 — current assets exceed current liabilities.
- Where does Kyverna Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.